Indivior Pharmaceuticals (INDV) Change in Accured Expenses (2024 - 2026)

Indivior Pharmaceuticals' Change in Accured Expenses history runs 3 years deep, the most recent figure standing at -$86.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 206.17% year-over-year to -$86.0 million; the TTM figure through Mar 2026 stood at -$126.0 million (down 241.57% YoY), while the FY2025 annual figure was $41.0 million, up 412.5% from the prior year.
• Change in Accured Expenses was -$86.0 million for Q1 2026 at Indivior Pharmaceuticals, down from -$8.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $81.0 million in Q1 2025 to a low of -$86.0 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$4.6 million across 3 years, with a median of $1.0 million in 2024.
• Biggest YoY gain for Change in Accured Expenses was 87.3% in 2025; the steepest drop was 920.0% in 2025.
• A 3-year view of Change in Accured Expenses shows it stood at -$63.0 million in 2024, then jumped by 87.3% to -$8.0 million in 2025, then slumped by 975.0% to -$86.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$86.0 million (Q1 2026), -$8.0 million (Q4 2025), and -$82.0 million (Q3 2025), per Business Quant data.